Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.
D000477:Alkylating Agents / Q000627:therapeutic use; D006585:Altretamine / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009420:Nervous System / Q000187:drug effects; D014227:Triazines / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D000477:Alkylating Agents; D014227:Triazines; D006585:Altretamine